Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC
Portfolio Pulse from
Immunome, Inc. has dosed the first patient in its Phase 1 trial of IM-1021, a ROR1-targeted ADC, marking a significant step in its cancer therapy development.
March 10, 2025 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immunome has initiated a Phase 1 trial for its ROR1-targeted ADC, IM-1021, by dosing the first patient. This marks a significant milestone in their cancer therapy development.
The initiation of a Phase 1 trial is a critical step in drug development, indicating progress in Immunome's pipeline. This could positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100